How Well Do Patients Really Know Their Own Skin Cancer History?

When dermatologists ask a new patient whether they have ever had skin cancer, the answer they receive often becomes a permanent part of the medical record. It shapes screening intervals, guides biopsy decisions, and influences how aggressively a clinician hunts for precancerous lesions during a full-body examination. Yet a new research letter published in the Archives of Dermatological Research raises an uncomfortable but essential question: how accurate are those patient-reported histories when it comes to actinic keratoses and keratinocyte carcinomas, the two most common sun-driven lesions dermatologists encounter?

The study, conducted by Joseph McGrath, Evelyn Fagan, Kaeli Samson, Yue Zhan, and Adam Sutton, was approved by the University of Nebraska Medical Center’s institutional review board and carried out in accordance with the Declaration of Helsinki, with written informed consent obtained from every participant. The research team set out to systematically compare what patients say about their own skin lesion histories against clinical verification, a comparison that matters enormously because the entire architecture of skin cancer surveillance in many health systems rests on self-reported data gathered in intake questionnaires and verbal histories.

Actinic keratoses are rough, scaly patches that develop on chronically sun-exposed skin, most often in fair-skinned, older adults. They are technically keratinocyte dysplasias rather than frank malignancies, but they occupy a critical position on the continuum of cutaneous carcinogenesis. A subset of them can progress to squamous cell carcinoma, and their presence signals what dermatologists call field cancerization, a state in which broad swathes of skin have sustained enough ultraviolet damage that multiple lesions can arise simultaneously and independently across the affected area. Keratinocyte carcinomas, meanwhile, encompass basal cell carcinoma and squamous cell carcinoma, the two most frequent cancers in fair-skinned populations worldwide and cancers whose incidence continues to climb as populations age and cumulative ultraviolet exposure accumulates.

The problem with relying on patient recall for these conditions is baked into their biology and their clinical course. Actinic keratoses are frequently treated with destructive methods such as cryotherapy, in which liquid nitrogen obliterates the lesion without any tissue being sent to a pathology laboratory. A patient who has had a dozen such treatments over twenty years may genuinely not know whether any given rough patch was confirmed as an actinic keratosis, whether it was something benign like a seborrheic keratosis, or whether it was an early squamous cell carcinoma that was frozen off preemptively. The diagnostic label often exists only in billing codes or in the memory of a clinician the patient saw years ago, if it exists at all.

Keratinocyte carcinomas present a related but distinct recall challenge. Basal cell carcinomas are rarely life-threatening but frequently recur, and patients with one history of nonmelanoma skin cancer face substantially elevated odds of developing subsequent lesions, a relationship established in meta-analytic work going back to Marcil and Stern’s widely cited 2000 review in the Archives of Dermatology. Squamous cell carcinomas carry greater metastatic potential, making accurate history-taking even more consequential. If a patient underreports a prior squamous cell carcinoma, a clinician may underestimate risk and calibrate follow-up too loosely. If a patient overreports, the result can be unnecessary anxiety, redundant biopsies, and wasted health system resources. Either direction of error degrades the precision of epidemiological studies that depend on self-reported cancer histories as their exposure variable.

This is not the first time the validity of patient self-report in dermatology has been scrutinized. A landmark 2004 study by Ming and colleagues, published in the same Archives of Dermatology, examined the validity of patient self-reported history of skin cancer and found meaningful discordance between what patients reported and what medical records could substantiate. That work, along with the more recent effort by Kitrell, Crew, Wysong, and Sutton in 2023 to refine the classification of field cancerization, frames the conceptual backdrop against which the new Nebraska-led study operates. The field cancerization concept itself, originally coined in the head and neck oncology literature and since extended to sun-damaged skin, implies that patients with field disease are precisely the ones most likely to have long, complicated lesion histories that strain the limits of lay recall.

Health literacy adds another layer of complexity. A 2024 systematic review by Chang and colleagues in the Journal of Prevention examined the role of health literacy in skin cancer preventive behavior and highlighted how unevenly patients understand even basic distinctions between lesion types. Many patients use the phrase skin cancer loosely, applying it to anything their doctor froze, burned, or scraped. Others with genuine histories of malignancy may not register the diagnosis because the encounter was brief, the terminology was unfamiliar, or the lesion was treated in a setting where pathology confirmation never occurred. In epidemiological surveys, in genetic studies recruiting participants on the basis of skin cancer history, and in clinical trials of field therapies, these misclassifications propagate quietly through the data.

The methodological stakes extend beyond the clinic into the research enterprise itself. Countless studies of keratinocyte carcinoma risk factors, from tanning bed use to immunosuppression to genetic susceptibility loci, rely on questionnaires asking participants whether a physician has ever told them they had skin cancer. Validation studies like the one from the University of Nebraska team provide the sensitivity and specificity estimates that allow researchers to correct for misclassification statistically. Without such grounding, effect estimates can be biased toward or away from the null in unpredictable ways, and the direction of bias often differs for actinic keratoses, which are over-reported when patients conflate them with benign barnacles of aging, versus keratinocyte carcinomas, which may be under-reported when pathology confirmation was never communicated clearly.

The practical implications for clinical practice are equally significant. Dermatologists performing surveillance on patients with a history of field cancerization already know that these individuals require more frequent examinations, and the new findings underscore that the history a patient volunteers should be treated as a starting point rather than a settled fact. Wherever possible, clinicians and researchers seeking accurate keratinocyte carcinoma histories should corroborate patient report with pathology records, tumor registries, or prior biopsy reports. For actinic keratoses, where confirmation is often impossible because destructive treatment leaves no tissue to examine, the study’s findings argue for building explicit uncertainty into both clinical documentation and research instruments, perhaps by distinguishing between patient-recalled lesions and provider-diagnosed, pathology-confirmed ones.

What makes this research letter notable is not that it overturns any single dogma but that it quantifies a vulnerability running through a vast body of dermatological science and everyday clinical care. The authors, who declare no competing interests and report no external funding, designed the study so that statistical analysis was performed by dedicated biostatisticians within the University of Nebraska Medical Center’s Department of Biostatistics, with McGrath and Fagan contributing equally to the work. Their data cannot be shared openly, a restriction that protects participant privacy under the informed consent agreements patients signed. As skin cancer incidence continues to rise and as health systems increasingly depend on patient-reported outcomes and self-administered intake tools, including digital questionnaires and telehealth screening algorithms, the gap between what patients believe about their own skin and what has actually occurred on it becomes a variable that medicine can no longer afford to ignore. This study is a measured, careful reminder that in dermatology, as in much of medicine, the patient’s memory is a diagnostic instrument, and like any instrument, it needs calibration.

Subject of Research: Accuracy of patient-reported histories of actinic keratoses and keratinocyte carcinomas

Article Title: Assessing the accuracy of patient-reported actinic keratoses and keratinocyte carcinomas

Article References: McGrath, J., Fagan, E., Samson, K., Zhan, Y., & Sutton, A. (2026). Assessing the accuracy of patient-reported actinic keratoses and keratinocyte carcinomas. Archives of Dermatological Research, 318(1), Article 489. https://doi.org/10.1007/s00403-026-04942-8

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04942-8

Keywords: actinic keratosis, keratinocyte carcinoma, skin cancer, patient self-report, dermatology, field cancerization, basal cell carcinoma, squamous cell carcinoma, health literacy, misclassification, skin cancer screening, epidemiology